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Staphylococcus aureus (S. aureus) is a Gram-positive pathogen causing a variety of
infections in humans and animals. Extensive use of antibiotics has led to the emergence
of methicillin-resistant S. aureus (MRSA). As an alternative antibacterial agent against
drug-resistant S. aureus, a lytic phage, designated SLPW, was isolated from fecal
sewage in a pig farm. The SLPW was morphologically classified under Podoviridae
and contains a double-stranded DNA genome. The genome of SLPW was 17,861
bp (29.35% G+C) containing 20 open reading frames and lacked regions encoding
lysogeny-related integrase gene and cI repressor gene. Phage SLPW showed a broad
host range and high efficiency of plating against various types of S. aureus. One-step
growth curve showed a short latency period (10 min) and a long lytic period (120 min).
Phage SLPW remained stable under a wide range of temperatures or pH and was almost
unaffected in chloroform or ultraviolet light. Further, it efficiently lysedMRSA strains in vitro
and in vivo. Intraperitoneal phage administration at 1 h post-infection cured the mice
and reduced the bacterial expression of inflammatory cytokines in mice. Specifically, the
phage SLPW displayed a wide antibacterial spectrum. It was therapeutically effective
against intra-abdominal infection in mice harboring different multilocus sequence typing
(MLST) types of S. aureus strains. Therefore, phage SLPW is a potential therapeutic
agent against MRSA infections.
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INTRODUCTION
Staphylococcus aureus (S. aureus) is the most virulent pathogen causing various diseases, including
skin abscesses, pneumonia, endocarditis, and osteomyelitis, in humans and animals (Lowy,
1998; Plata et al., 2009). The two major sources of infection include community and hospital
(Engemann et al., 2003). The bacterial strains are resistant to many antibiotics, and especially
to methicillin and vancomycin. The emergence and prevalence of methicillin-resistant S. aureus
(MRSA) and vancomycin-resistant S. aureus (VRSA) underscores the need for development of
effective therapeutic alternatives (Sasidharan et al., 2011; Gardete and Tomasz, 2014).
In the last 15 years, there has been a marked increase in the number of identified Staphylococcus
phages, with tremendous progress in therapeutic interventions targeting Staphylococcus, especially
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S. aureus (Hsieh et al., 2011). Phages are the most common
organisms on the planet and represent great diversity in host
range. S. aureus phages target pathogens in diseases, such
as bacteremia, eye infections, and S. aureus-associated lung
infections (Wills et al., 2005; Kazmierczak et al., 2015). Compared
with traditional antibiotics, bacteriophages are cost-effective
without serious side effects, and are virulent especially against
drug-resistant bacteria (Borysowski et al., 2011; Kazmierczak
et al., 2015). Further, phages generally recognize specific
receptors on bacterial cell membrane, without affecting human,
or animal cells. Therefore, the side effects in eukaryotic hosts are
minimal (Sulakvelidze et al., 2001). Studies involving S. aureus
phages show effective and comprehensive antimicrobial activity
in vitro and in vivo (Capparelli et al., 2007; Gutierrez et al., 2015).
In this study, we isolated a lytic phage, SLPW, from
fecal sewage in a pig farm. We report the wide host range,
adequate stability and strong bacteriolytic activity of this phage.
Specifically, the phage SLPWwas safe and effective againstMRSA
infection in mice.
MATERIALS AND METHODS
Ethics Statement
Animal experiments were carried out according to the animal
welfare standards approved by the Ethical Committee for Animal
Experiments of Shanghai Jiao Tong University, China. All animal
experiments complied with the guidelines of the Animal Welfare
Council of China.
Bacterial Strains and Culture Conditions
In this study, 38 S. aureus strains (18 MRSA strains, 7 clinically
isolated pathogenic strains and 13 strains isolated from milk
samples of dairy cows with mastitis) and 8 other strains
(Staphylococcus epidermidis ATCC12228, Bacillus subtilis YS, S.
zooepidemicus ATCC35246, 4 Streptococcus suis and Escherichia
coli MC1061) were used (Table 1). Two reference strains of S.
aureus ATCC 25923 and ATCC 29213 from the American Type
Culture Collection (ATCC) were also used. All the strains were
grown in Todd–Hewitt broth (THB) and brain heart infusion
(BHI) or agar medium supplemented with 2% (vol/vol) fetal
bovine serum (Gibco, Invitrogen Corp., Carlsbad, CA) at 37◦C.
Phage Isolation, Purification, and Host
Range Determination
The method of Matsushiro et al. was adopted for the isolation
of S. aureus phages with some modifications (Matsushiro and
Okubo, 1972). Seventy-four samples, including 44 dust swabs
and 30 fecal samples were suspended in SM buffer [NaCl 5.8
g/L, MgSO4·7H2O 2 g/L, 1 M Tris·HCl (pH7.5) 50 ml/L, and 2%
gelatin 5ml/L] and centrifuged at 5000× g for 20min at 4◦C. The
supernatants were filtered through 0.22-µm pore membranes
and evaluated for the presence of lytic phages using different
S. aureus isolates on BHI plates. After overnight incubation,
bacterial plaque formation suggested the presence of lytic phage,
which was purified after three rounds of single-plaque isolation.
For purification, a single-phage plaque was precipitated in the
presence of 10% (wt/vol) polyethylene glycol (PEG) 8000 and 1
TABLE 1 | SLPW strains and lytic activity
Species of strain No. of strain MLST type EOPa Sourceb
Staphylococcus
aureus (22)
ATCC25923 ST 243 1 III
ATCC29213 ST 5 1.37 × 10−5 III
S1 ST 398 4.24 × 10−6 I
S2 ST 239 6.12 × 10−1 I
S3 ST 239 — I
S4 ST 239 2.13 × 10−1 I
S5 ST 398 6.33 × 10−1 I
S6 ST 9 — I
S7 ST 239 8.22 × 10−5 I
SH-5 ST 9 2.32 × 10−1 II
SH-6 ST 9 5.44 × 10−7 II
SH-7 ST 9 7.21 × 10−6 II
SH-8 ST 9 8.14 × 10−1 II
SH-9 ST 9 2.02 × 10−1 II
SH-10 ST 9 4.37 × 10−1 II
SH-11 ST 9 2.62 × 10−1 II
SH-12 ST 9 4.23 × 10−1 II
SH-13 ST 9 4.22 × 10−5 II
SH-14 ST 9 9.17 × 10−6 II
SH-15 ST 9 1.98 × 10−1 II
SH-16 ST 9 2.82 × 10−6 II
Methicillin-resistant
Staphylococcus
aureus (18)
SH-17 ST 9 1.81 × 10−1 II
MS3 ST 9 1.62 IV
MS5 ST 5 7.52 × 10−1 IV
MS6 ST 5 2.88 × 10−1 IV
MS7 ST 5 7.23 × 10−1 IV
MS8 ST 9 8.22 × 10−1 IV
MS9 ST 9 8.21 × 10−1 IV
MS10 ST 239 2.82 × 10−6 IV
MS11 ST 9 4.33 × 10−1 IV
MS13 ST 9 8.22 × 10−1 IV
MS15 ST 5 8.17 × 10−1 IV
MS16 ST 9 9.23 × 10−1 IV
MS17 ST 398 4.33 × 10−5 IV
MS18 ST 9 3.22 × 10−1 IV
MS19 ST 9 2.98 × 10−1 IV
MS20 ST 398 1.23 × 10−1 IV
MS21 ST 398 1.67 × 10−1 IV
MS22 ST 398 — IV
MS23 ST 9 — IV
Staphylococcus
epidermidis
ATCC12228 —c — IV
Bacillus subtilis YS — — IV
Streptococcus suis SS1 — — IV
SS2 — — IV
SS7 — — IV
(Continued)
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TABLE 1 | Continued
Species of strain No. of strain MLST type EOPa Sourceb
SS9 — — IV
Streptococcus
zooepidemicus
ATCC35246 — — III
Escherichia coli MC1061 — — IV
aEOP, efficiency of plating (EOP = phage titer on test bacterium / phage titer on host
bacterium Staphylococcus aureus ATCC25923). Assays were conducted at least three
times. The data shown represent means derived from three independent experiments.
b I, clinically-isolated pathogenic strains; II, isolated from milk samples of dairy cows with
mastitis; III, purchased from American Type Culture Collection; IV, stored in our lab.
c—, no plaque on target bacterium.
M NaCl at 4◦C for at least 1 h. The precipitate was collected by
centrifugation at 10,000 × g for 10 min at 4◦C and suspended
in SM buffer. After the addition of 0.5 g/mL CsCl, the mixture
was layered on top of CsCl step gradients (densities of 1.15,
1.45, 1.50, and 1.70 g/mL) in Ultra-Clear centrifugation tubes
and centrifuged at 28,000 × g for 2 h at 4◦C, and dialyzed in
sodium chloride–magnesium sulfate buffer [100 mM NaCl, 10
mMMgSO4·7H2O, and 50 mM Tris·HCl (pH 7.5)]. Phages were
stored at 4◦C for further experiments.
The host range of the phage was defined by the double-layered
agar method described by Adams (1959). The SLPW phage was
inoculated with all the 47 strains listed in Table 1 and then
monitored for plaque formation.
Transmission Electron Microscopy (TEM)
of Phage Particles
The purified phage sample was loaded onto a copper grid for
7 min followed by negative staining with 2% (vol/vol) uranyl
acetate (pH 6.7) and drying. The phagemorphology was observed
using a FEI TEM Tecnai G2 Spirit Biotwin (FEI, Hillsboro, US)
at an accelerating voltage of 80 kV.
Restriction Enzyme Digestion of Phage
Genomic DNA
Purified phage genomic DNA was prepared as described
previously by Son et al. (2010). For the identification of nucleic
acid type, purified phage genomic DNAwas subjected to nuclease
treatment using DNase I (20 U/µL), RNase A (5 U/µL), and
Mung bean nuclease (20 U/µL) at 37◦C for 1 h. Restriction site
analysis of the phage was conducted by digesting purified phage
genomic DNA with 10 U Xho I, EcoR I, Hind III, Ned I, and Not
I for 1 h at 37◦C. Products of digested phage nucleic acid were
separated by 0.8% (wt/vol) agarose gel electrophoresis.
Genome Sequencing and Annotation
Shotgun sequencing was used for Phage SLPW whole genome
analysis. Sequence alignments were carried out using the Accelrys
DS Gene software package of Accelrys Inc. (USA). Putative
open reading frames were suggested using the algorithms of the
software packages Accelrys Gene v2.5 (Accelrys Inc.) and ORF
Finder (NCBI). Identity values were calculated using different
BLAST algorithms (http://www.ncbi.nlm.nih.gov/BLAST/) at the
NCBI homepage. The sequence of phage SLPW has been
submitted to NCBI (GenBank accession number: KU992911).
Assay of Optimal Multiplicity of Infection
(MOI)
Overnight cultures of S. aureus ATCC 25923 strain were diluted
1:100 in fresh BHI and incubated at 37◦Cwith shaking until early
logarithmic growth phase (optical density at 600 nm, 0.4–0.6),
diluted 1:10, and mixed with phages at different MOIs. After 3.5
h incubation at 37◦C, the mixture was centrifuged at 5000× g for
20 min at 4◦C and the supernatants were filtered through 0.22-
µmporesize membranes. The phage titer in the supernatant was
immediately determined using a double-layer agar plate method.
This assay was performed at least in triplicate.
One-Step Growth
For determination of one-step growth of phage SLPW, we used
S. aureus ATCC 25923 as the host strain because it displayed
the largest clearance zone in a spot test and was lysed rapidly to
yield a clear lysate in liquid culture. One-step growth experiments
were performed using a modified method described previously
(Pajunen et al., 2000). Briefly, SLPW phage was added at a MOI
of 0.1 to the cells of S. aureus and allowed to adsorb for 15 min
at 37◦C. The mixture was then centrifuged at 10,000 × g for 1
min. After the supernatants were removed, the pellets containing
the phage-infected bacterial cells were suspended in fresh BHI
and incubated with shaking at 180 rpm and 37◦C. Partial samples
were obtained at 10 min intervals and the titrations from the
aliquots were immediately determined using the double-layer
agar plate method. This assay was performed at least in triplicate.
Phage Stability
Phage stability was determined at different temperatures (25, 37,
45, 50, 55, 60, 65, and 70◦C), using an aliquot of phage SLPW
obtained after 1 h. The titers of the phage lysate were assayed
using a double-layer agar plate method. The phage stability at
different pH-values was tested by determining the titers after
dilution of the phage lysates (1:100) in SM buffer and stored at
37◦C for 3 h. To analyze the chemical stability, the phage SLPW
was treated with chloroform (5, 25, 50, or 75%, vol/vol) for 6,
12, 18, and 24 h at 4◦C. In addition, the phage SLPW was also
exposed to ultraviolet light treatment for 10, 20, 30, 40, 50, and
60 min, and titrated immediately using a double-layer agar plate
method.
Efficiency of Plating
Phage SLPW was screened against S. aureus strains using
the efficiency of plating method (EOP = phage titer on test
bacterium/phage titer on host bacterium) to determine the
effectiveness against a variety of target bacteria. Ten-fold serial
dilutions of phage suspensions (100 µL) were mixed with 100 µL
of the target or host bacterium (grown overnight at 37◦C) and
incubated for 5 min at room temperature (25◦C) and plated as
double layers on THB (Viscardi et al., 2008).
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Phage Bacteriolytic Activity In vitro
Overnight cultures of S. aureus culture were diluted 1:100 in
fresh THB liquid medium incubated at 37◦C with shaking at
180 rpm until an early-exponential host bacterial culture (optical
density at 600 nm, 0.4–0.6) was reached. Phage SLPW was added
at MOI of 0.01, 1, and 100, and an identical S. aureus culture
with the same volume phage diluent was used as the control. The
mixture was then grown at 37◦C with shaking at 180 rpm. The
phage bacteriolytic activity was assessed by monitoring the cell
absorbance of the culture solution (OD600) at 30-min intervals
for up to 4 h, and this assay was performed in triplicate.
Phage Protection Studies
Female BALB/c mice (6 weeks of age) were purchased from the
Experimental Animal Center, Shanghai Jiao Tong University.
Overnight cultures of S. aureus were diluted 1:100 in fresh THB
liquid medium incubated at 37◦C with shaking at 180 rpm to
an early-exponential host bacterial culture (optical density at
600 nm, 0.4–0.6). Cells were pelleted and washed twice with
phosphate-buffered saline (PBS). The mice were infected with
a dose of 1 × 109 CFU in 0.2 mL of the S. aureus strain.
The bacterial cells were injected unilaterally into the abdominal
cavities of mice, and 0.2 mL of the purified phage samples (1 ×
109 PFU) were injected into the other side immediately, at 60
and 120 min after a bacterial challenge. The controls included
uninfected mice administered with 0.2 mL of phage in SM buffer.
The mouse survival rate was recorded daily for 7 days. The CFU
or PFU organ burden in spleen, lung, and blood was determined
by sacrificing groups of six mice at 6, 12, and 24 h after phage
SPLW administration. Each sample was homogenized in 1 mL
PBS and serially diluted in PBS. CFU were evaluated by plating
each dilution on THB agar plates. The PFU were evaluated by
plating each dilution on the double-layer agar plate.
Cytokine Assays
To evaluate the antimicrobial effects of phage, 0.2 mL of phage
in SM buffer (1 × 109 PFU) was administered intraperitoneally
at 1 h after infection with S. aureus (1 × 109 CFU). SM buffer
alone was administered to uninfected mice serving as control
groups. Spleen tissues were removed from mice 6, 12, and 24
h after injection with phage SLPW. Tissues were homogenized
in 1 mL of lysis buffer (Qiagen, West Sussex, UK), followed by
centrifugation at 2000 × g for 10 min. The supernatants were
sterilized with a millipore filter (0.45-µm pore size).
Total RNA was isolated from the supernatants using an
AllPrep RNA microkit (Qiagen). The cDNA synthesis was
performed using the PrimeScript RT reagent kit (TaKaRa, Dalian,
China) according to the manufacturer’s instructions. The mRNA
levels were measured using two-step relative qRT-PCR. The β-
actin housekeeping gene was amplified as an internal control.
The sequences of the primers for tumor necrosis factor alpha
(TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and β-actin
are listed in Table 2. Gene expression was normalized to the
expression of the housekeeping gene β-actin. Real-time PCR
was performed using a SYBR Premix Ex Taq kit (TaKaRa) and
CFX ConnectTM RT-PCR system (BIO-RAD, Hercules, USA).
TABLE 2 | Primers used for qRT-PCR
Primer Sequence (5′–3′)
IL-1β-F TCCAGGATGAGGACATGAGCAC
IL-1β-R GAACGTCACACACCAGCAGGTTA
IL-6-F CCACTTCACAAGTCGGAGGCTTA
IL-6-R GCAAGTGCATCATCGTTGTTCATAC
TNF-α-F AAGCCTGTAGCCCACGTCGTA
TNF-α-R GGCACCACTAGTTGGTTGTCTTTG
β-actin-F TGACAGGATGCAGAAGGAGA
β-actin-R GCTGGAAGGTGGACAGTGAG
FIGURE 1 | Transmission electron microscopy of negatively-stained
phage SLPW.
The comparative cycle threshold (2−11CT) method was used to
analyze the mRNA levels.
Statistical Analyses
Experimental data points were plotted using GraphPad Prism 5
(GraphPad Software, Inc., San Diego, CA). Data were expressed
as mean values ± standard errors of the means (SEM). The
phage protection analyses were performed using the non-
parametric Mann-Whitney U-test. A P < 0.05 was considered
significant.
RESULTS AND DISCUSSION
Phage Isolation and Host Range
Determination
In this study, we isolated a lytic S. aureus phage designated as
SLPW, from fecal sewage in a pig farm of Shanghai (China)
in 2013. Using S. aureus ATCC25923 as the host strain, the
phage plaques measuring 1–2 mm in diameter were obtained.
The phage SLPW had a strong ability to produce plaques on
S. aureus strains. Among the 40 S. aureus strains, 36 (90%)
isolates were lysed by SLPW (Table 1). Furthermore, the SLPW
phage showed strong lytic activity against the majority of MRSA
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strains (16 of 18 strains), suggesting a potential therapeutic
role in MRSA infection. However, no plaque production was
observed in Staphylococcus epidermidis, Bacillus subtilis, S.
zooepidemicus, Streptococcus suis, and E. coli strains investigated
(Table 1).
The morphology of the isolated phage SLPW was determined.
Electron microscopy showed that the SLPW particle had an
isometric head of 49.5 ± 1.5 nm and a short, non-contractile
tail measuring 19.5 ± 1.5 nm long (Figure 1). Thus, it was
morphologically similar to phages of the family Podoviridae
FIGURE 2 | Agarose gel electrophoresis of phage SLPW genome
digested with nuclease. Lane M: λ-Hind III digest DNA Marker, Lane 1–3:
phage SLPW genome digested with RNaseA, DNase I, and Mung Bean
Nuclease, respectively.
FIGURE 3 | Restriction digestion patterns of phage SLPW DNA. Lane
M1: λ-Hind III digested DNA Marker, Lane 1: phage SLPW genome, Line 2–6:
phage SLPW genome digested with Xho I, EcoR I, Hind III, Ned I, and Not I,
respectively, Line M2: DL 15000+2000 marker.
according to the classification of International Committee on
Taxonomy of Viruses (ICTV; Adams et al., 2014).
Phage Nucleic Acid Type and Genome
Description
The purified phage genomic DNA was subjected to digestion
by different nucleases. The results showed that the genome
of phage SLPW was completely digested by DNase I but not
by RNase A or Mung bean nuclease (Figure 2), suggesting
that phage SLPW was a double-stranded DNA. Purified phage
SLPW genomic DNA could be digested with several restriction
endonucleases including Xho I, EcoR I, Hind III, and Ned I
(Figure 3).
The complete nucleotide sequence of phage SLPW was
determined. The SLPW genome comprises 17,861 bp with an
average G+C content of 29.35%, which is similar to that of
the lytic Staphylococcus phages S13’, PSa3, and 66 (Table S1).
TABLE 3 | Optimal multiplicity of infection (MOI) of phage SLPW.
CFU of S. aureus
ATCC25923 strain
PFU of
phage SLPW
MOI Phage SLPW
titers (PFU/mL)
106 108 100 3.32 × 109
107 108 10 2.71 × 109
108 108 1 3.12 × 1010
108 107 0.1 4.87 × 1010
108 106 0.01 2.92 × 108
108 105 0.001 4.41 × 107
108 104 0.0001 3.37 × 106
FIGURE 4 | One-step growth curve of phage SLPW in S. aureus. Phage
SLPW was co-incubated with S. aureus ATCC25923 strain cultured at an MOI
of 0.1 for 15 min at 37◦C. The mixture was centrifuged to remove
non-absorbed phage. The re-suspended pellets were incubated at 37◦C and
sampled at 10 min intervals over a period of 3 h. Phage titer was measured.
Results are shown as means ± SEM from triplicate experiments. The latent
period was 10 min: interval between the absorption and the beginning of the
initial burst. The burst size was estimated at 95.3 PFU per infected cell, which
was the ratio of the final count of liberated phage particles to the initial count of
infected bacterial cells.
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FIGURE 5 | Stability tests of phage SLPW. (A) Thermostability: Phage SLPW was incubated at various temperatures as indicated. Samples were collected after 1
h; (B) pH stability: Phage SLPW was incubated under different pH conditions for 3 h; (C) Chloroform stability: Phage SLPW was treated with chloroform (5, 25, 50, or
75%, vol/vol) for 6, 12, 18, and 24 h; (D) Ultraviolet light stability: Phage SLPW was exposed to UV light for 10, 20, 30, 40, 50, and 60 min. The overall results were
expressed as survival rates, and were titrated immediately using double-layer agar plate method. Results are shown as means ± SEM from triplicate experiments.
FIGURE 6 | Bacteriolytic activity of SLPW against S. aureus in vitro. Early exponential cultures of S. aureus (A) ATCC25923 and (B) MS3 strains were
co-cultured with SLPW phage at MOIs of 0.01, 1, and 100, respectively. S. aureus cultured with a similar volume of phage diluent was used as a control. Results are
shown as means ± SEM from triplicate experiments.
As shown in Table S2, 20 open reading frames (ORFs) were
defined as potential genes of SLPW. Genes involved in packaging,
head, tail, lysis, and DNA replication showed high homology
with other phages listed in Figure S1 and Table S2 (Kwan et al.,
2005). However, a few unknown proteins of SLPW including
Gp4, Gp6, and Gp20 showed a lower degree of similarity than
those of other Podoviridae Staphylococcus phages (Table S2),
which may lead to functional discrepancy. The genes of SLPW
encoding lysin (Gp14) and holin (Gp10) showed high similarity
with Staphylococcus lytic phages listed in Table S2, which also
showed a broad host range and strong lytic ability against S.
aureus (Kraushaar et al., 2013). Comparison of the genome
structure with Staphylococcus prophages suggested that SLPW
was a lytic phage, which lacked specific integration-related and cI
repressor genes, devoid of lysogenic characteristics (Kwan et al.,
2005; Hoshiba et al., 2010; Biswas et al., 2014).
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Determination of Optimal Multiplicity of
Infection (MOI) and One-Step Growth
Curve
The results showed that the optimal MOI of phage SLPW was
0.1, which was the highest titer attained by the phage lysates
(4.87 × 1010 PFU/mL; Table 3). Based on the optimal MOI, we
established a one-step growth curve. Short latency period (10
min) and large burst size (estimated at 95.3 PFU per infected cell;
Figure 4) suggest lytic nature of the SLPW phage and a higher
FIGURE 7 | Survival curves of mice infected with S. aureus MS3 strain
and treated with phage SLPW. Phage (MOIs of 1) was administered
intraperitoneally into mice at 0, 1, or 2 h post-infection and the survival rates
were recorded. Data shown are representative of three independent
experiments using 10 mice per group, and displayed as mean ± SEM.
lytic activity than the previously published lytic S. aureus phages
(Han et al., 2013; Li and Zhang, 2014).
Phage Stability
The potential clinical role of phage SLPW was evaluated by
determining their physical and chemical stabilities. The thermal
stability of the phages was investigated at different temperatures.
We found that the activity of phage SLPW was stable at
temperatures up to 45◦C. Higher temperatures resulted in
progressive inactivation. Phage SLPWwas completely inactivated
when heated to 65◦C (Figure 5A). The pH stability was studied
in SM buffers at a pH range of 2–12. Phage SLPW showed a
relatively high survival rate (more than 80%) at a pH ranging
from 6 to 10. Beyond these values, the activity decreased
dramatically (Figure 5B). Further, the viability of phage SLPW
was almost unaffected in the presence of 5, 25, 50, and 75%
chloroform as shown in Figure 5C. Ultraviolet irradiation assay
showed that about 90% of phage SLPW survived UV light (30
w, 30 cm wave-length) treatment ranging from 10 to 60 min
(Figure 5D).
Studies suggested a probable relationship between phage
structure and survival under adverse environmental conditions
(Lasobras et al., 1997). Ackermann et al indicated that tailed
phages remain comparatively steady in adverse conditions
(Ackermann et al., 2004). Under harsh conditions, such as strong
ultraviolet light, and large temperature fluctuations, phages
belonging to Myoviridae protect themselves from extremely
dry environment via intercellular location in pseudo-lysogens
FIGURE 8 | Survival curves of mice infected with different S. aureus strains and treated with phage SLPW. Phage (MOIs of 1) was injected intraperitoneally
into mice at 1 h post-infection and the survival rates were recorded. Infected mice treated with SM buffer served as control. Data shown are representative of three
independent experiments using 10 mice per group, and displayed as mean ± SEM.
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FIGURE 9 | S. aureus concentrations in the blood and organs of mice treated with phage SLPW at 1 h post-infection. Six mice were sacrificed from each
mouse group at different time points. SM buffer was administered to infected mice, which served as control. Results are shown as means ± SEM from triplicate
experiments. The Mann-Whitney U-test was used to compare the phage concentration data. Significant differences (P < 0.01) are indicated by asterisks.
FIGURE 10 | Figure 10 Phage SLPW concentrations in the blood and
organs of mice treated with phage SLPW at 1 h post-infection. Six mice
were sacrificed from each group at 24 h after the experiment. Phage was
injected into uninfected mice, which served as controls. Results are shown as
means ± SEM from triplicate experiments. The Mann-Whitney U-test was
used to compare the phage concentration data. Significant differences (P <
0.01) are indicated by asterisks.
or biofilms created by bacterial hosts (Jonczyk et al., 2011).
Phages from Podoviridae family may be extremely resistant to
dry environment and survive large temperature fluctuations
(Prigent et al., 2005). Our studies suggest that SLPW, which
belongs to Podoviridae, showed a broad range of thermal and pH
stability and strong resistance to chloroform and ultraviolet light
treatment. Based on the above studies, tailed phages generally
show great ability to adapt to adverse conditions, contributing to
the development of phagotherapy.
Bacteriolytic Activity In vitro
The phage SLPW bacteriolytic activity was tested in an early-
exponential phase culture of S. aureus ATCC25923 and MS3
strains. The growth of these strains steadily declined at an
MOI 1 and was completely inhibited at MOI 100 directly after
phage administration (Figure 6). However, when the culture was
administered using phage SLPW at MOI 0.01, the absorbance
(OD600) continued to increase during the incubation (Figure 6).
The results suggested that SLPW was highly effective against
S. aureus in vitro and an MOI 1 was used for therapeutic
study in vivo.
Phage Therapeutic Study
Although studies indicate successful outcomes with topical phage
treatment of human and animal infections involving S. aureus,
few studies focused on the treatment of acute and lethal infection
(Chhibber et al., 2013; Pincus et al., 2015). To investigate the
virulence of MRSA strain MS3 in BALB/c mice, the mortality of
mice was recorded daily, and followed over a period of 7 days
after infection. Injection with 1 × 109 and 1 × 107 bacterial
cells resulted in 100 and 0% death, respectively (data not shown).
These doses were therefore used in subsequent experiments.
To evaluate the therapeutic potential of phage SLPW in
vivo, assays were performed using BALB/c mice after infection
with high concentrations of S. aureus (1 × 109 CFU/mouse).
The results showed that mice treated with phage immediately
(0 h) or at 1 h post-infection showed significantly higher
survival rates than the control groups (infected mice treated
with SM buffer) after 7 days. The survival rates following
phage therapy at 0, 1, and 2 h were about 80, 80, and 50%
after 7 days, respectively (Figure 7). Recent studies have shown
that immediate phage treatment provided better protection
than delayed administration against bacterial infection in mice
(Watanabe et al., 2007; Hsieh et al., 2011). However, our study
indicated that the survival rates between immediate and delayed
therapy (1 h post-infection) by phage SLPW were similar
(Figure 7). This finding confirmed that phage SLPW showed
higher efficiency and sensitivity against S. aureus in vivo. In
addition, phage SLPW exhibited satisfactory therapeutic effect
against different sequence types of S. aureus following multilocus
sequence typing (MLST; Figure 8).
Treatment efficacy was evaluated by examining bacterial
colonization in the organs and blood of mice after phage therapy
(1 × 107 PFU/mouse) following 1 h of infection with a non-
lethal dosage of S. aureus (1 × 107 CFU/mouse). Mice infected
with S. aureus strains showed relatively high pathogen density
in organs (Takemura-Uchiyama et al., 2014; Li et al., 2015).
However, the mice treated with SLPW showed significantly
lower S. aureus levels in the spleen and lung than the control
groups at every time point (Figure 9) suggesting that SLPW
was therapeutically effective against systemic infection caused by
S. aureus. However, the S. aureus concentrations in the blood
of the phage-administered groups were slightly lower than in
the control groups (Figure 9). The results also showed that
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FIGURE 11 | Levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in the spleens of mice treated with phage SLPW at 1 h after infection. Six
mice were sacrificed from each mouse group at different time points. SM buffer was administered to uninfected control mice. The values of pro-inflammatory
cytokines in the control groups were normalized to 1.0. Levels of IL-1β, IL-6, and TNF-α mRNA were normalized to β-actin mRNA levels and were expressed as n-fold
increases with respect to the control. Results are shown as means ± SEM from triplicate experiments. The Mann-Whitney U-test was used to compare the cytokine
levels between infected groups and treatment groups. Significant differences (P < 0.001) are shown by asterisks.
phage titers in the blood and organs at 24 h after therapy
were significantly increased by nearly four orders of magnitude
in the spleen and two orders of magnitude in the blood and
lung compared with those in the uninfected control groups
(Figure 10). Based on these results, we confirmed that SLPW
contributed to resistance to S. aureus and enhanced mouse
survival. Unfortunately, the therapeutic effect of SLPW in
uninfected control mice was temporary (Figure 10) and phage
therapy before infection with S. aureus showed no effect on
survival (data not shown).
The strength and efficiency of the host immune response
depends on the level of pro-inflammatory cytokines including
IL-1β, IL-6, and TNF-α, which are indicators of the severity of
infection (Wang et al., 2014; Lee et al., 2015). The results showed
that phage therapy of uninfected mice (medium-treated groups)
did not alter the cytokines levels (Figure 11). Therefore, phage
treatment was considered safe in mice and cytokine experiments
showed no bias. The IL-1β, IL-6, and TNF-α mRNA levels were
significantly lower in the phage-administered mice (treatment
groups) than in untreated mice (infected groups) at every time
point (Figure 11). The results suggested that phage treatment
successfully attenuated inflammation caused by S. aureus inmice.
The adverse effects associated with bactericidal agents include
the release of large amounts of pathogen-associated molecular
patterns recognized by Toll-like receptors and induction of pro-
inflammatory cytokines in mammals (Ginsburg, 2002; Horner
and Raz, 2003). However, our studies showed that treatment
of uninfected mice with phage SLPW showed no significant
differences in the expression of pro-inflammatory cytokines (IL-
1β, IL-6, and TNF-α) during 24 h (Figure 11). In addition,
phage therapy of uninfected mice resulted in similar survival
as mice injected with normal saline after 7 days (data not
shown). Our findings suggest that therapy using phage SLPW
was safe, although phage residues in tissuesmay influence normal
microflora in the human body (Endersen et al., 2014). Therefore,
active therapy using phage SLPW is expected to be effective in the
treatment of severe systemic infection caused by S. aureus.
CONCLUSION
In conclusion, our study investigates a lytic phage SLPW, which
exhibits a wide host range, strong lytic activity and relative
stability under various conditions. Rodent studies demonstrate
a protective role of the phage SLPW in mice against MRSA
infection, suggesting a potential antimicrobial role. Controlled
clinical studies are needed to investigate the findings in animal
studies.
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